A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of An Intravenous Bolus Infusion Pf-05230907 In Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 04 May 2016
At a glance
- Drugs PF 5230907 (Primary)
- Indications Cerebral haemorrhage
- Focus Adverse reactions
- Sponsors Pfizer
- 20 Apr 2016 Status changed from recruiting to completed.
- 07 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016, according to ClinicalTrials.gov record.
- 07 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Mar 2016, according to ClinicalTrials.gov record.